Quintiles Library

Harnessing Vital Data Image
Featured White Paper

Harnessing vital data to inform an optimal market access strategy in the UK
Market access now demands closer collaboration between biopharma, payers and providers. In a climate where ongoing reimbursement of a drug relies on biopharma’s ability to demonstrate how it delivers value to the entire healthcare system, partnership working is essential. Outcomes audits should be seen as one of the most important tools available to biopharma. They deliver detailed action plans to both biopharma and the NHS, proposing improvements to the care pathway...
Show Filters
Press Release
SEOUL, SOUTH KOREA – November 19, 2014 – Quintiles announced today that it has been recognized as one of South Korea’s Best Workplaces by the Great Place to Work® Institute. This is Quintiles Korea’s first time to receive the award; it joins many other Quintiles’ offices worldwide similarly honoured by the Great Place to Work Institute. Quintiles Korea was a “Grand Award” winner – the highest level – from among more than 100 companies in South Korea that participated in this year’s study. The Great Place to Work Institute annual ranking is a comprehensive study of organizational culture and also the world’s largest and most respected study of workplace excellence and people management practices. MiSook Hyun, General Manager of Quintiles Korea, said: “This award affirms our efforts to...
Read More
Media Coverage
Feature article published in the November 2014 edition of International Clinical Trials with input from Quintiles on conducting clinical trials in an international setting, with specific focus on the Middle East, North African...
Read More
Fact Sheet
As your products age, the pressure to shrink costs and grow revenue continues to increase. To effectively manage your portfolio, you need to do more than simply meet regulatory requirements. By aligning all aspects of marketed product maintenance, Quintiles can help you maximize value and manage safety. It’s what we call value vigilance. Learn how Quintiles can help maximize your product’s...
Read More
Fact Sheet
Meeting the demands of today’s drug development environment requires  flexibility. When looking for a long term central laboratory solution, it’s important to find a partner that can accommodate your needs for staffing, expertise and logistics as your product pipeline evolves. Quintiles central labs is here to help with clean data, faster logistics, and custom solutions built to meet the needs of your...
Read More
Fact Sheet
With Quintiles as your partner, you can build a world-class clinical diagnostics and medical devices company. Improve your probability of success with innovative ideas to commercially manage existing product lines and launch new technologies with a range of flexible options. Learn...
Read More
Presentation
Big Data is big business. As technology advances and more information about healthcare is recorded and stored, the opportunities for turning information into insight to improve outcomes have never been greater. It is no surprise that it is those most able to collect and, crucially, interpret this data who are pushing the boundaries of what is possible in market access. In the new health economies, biopharma needs to work much harder to meet the demands of stakeholders for robust evidence of exactly how a product will lead to better patient outcomes in the real world. Compelling data lies at the very heart of this challenge. What do payers and providers want to see from Big Data? Where are the gaps, and how can the information be better manipulated and localized? Should we be expanding...
Explore More
Video
Eric Faulkner, Practice Leader, Consulting at Quintiles discusses innovative and regenerative therapies and how companies must approach evidence generation, pricing and HTA differently.  He highlights the importance of a strong value story to overcome the complexities involved with such...
Video
Eric Faulkner, Practice Leader, Consulting at Quintiles discusses the impact on HTA and budget holders of an increasing trend towards personalized medicines and orphan drugs.  He highlights considerations such as how to value medicines amidst increasing cost scrutiny and how we adapt to this environment in this area to ensure that these valuable products are made available to...
Video
Anke van Engen, Senior Director, Consulting at Quintiles discusses statistical issues in analysing data to meet HTA authorities needs as they assess oncology products.  She highlights variations in approaches by different national authorities and how complex statistical methods can be used to ensure data quality for studies in which patients change treatment during the trial...
Media Coverage
Quintiles Employee Tess Brennan lived with atypical symptoms from a medical condition for more than 20 years trying to understand why she constantly felt tired and was experiencing bone pain and tenderness around her stomach. In 2012, she finally learned that she had been suffering from hepatitis-C, most likely for most of her life. As a Quintiles employee and 20-year veteran of clinical research, Tess enrolled in a clinical trial at Duke University Hospital in Durham, North Carolina. She soon learned the trial was being managed by her employer, Quintiles. The combination of three drugs which Tess took over an eight-week period quickly took her viral load from more than 10 million down to 47 and then to zero. After six months of being virus free, Tess’ doctors proclaimed her cured of...
Read More
Press Release
RESEARCH TRIANGLE PARK, NC – November 7, 2014 – Quintiles CEO Tom Pike will present at the Credit Suisse Healthcare Conference on Tuesday, November 11, 2014 in Phoenix at the Arizona Biltmore. The Quintiles presentation will begin at 10:00 a.m. (MST). Investors may access a live audio webcast of the presentation on the Quintiles’ Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling...
Read More
Media Coverage
Successful market access requires insights on strategic key decisions at the national level. Outsourcing to experts who understand the unique market access challenges of the German healthcare system could help smooth the path when entering Europe's biggest pharma market.   This article outlines how you can tackle the challenges of sustainable market access through successfully navigating marketing, reimbursement and product positioning within the stakeholder framework. The challenges North American biopharma companies face when entering the European marketplace, the options they have for overcoming these risks, and how to choose the best approach. Authors: Jeremy Broadis, Vice President, International, at Quintiles, UK & Dr. Birgit Friedmann, Senior Director Market Access at Quintiles...
Read More
Fact Sheet
The vaccine industry is full of promise with more than 450 new vaccines in clinical development, yet significant barriers to the advancement of vaccine clinical trials exist. To help address these challenges, Quintiles’ dedicated team of vaccine experts enabled by a global network of high-enrolling vaccine hubs and technology platforms aim to deliver rapid and predictable timelines and more cost-effective vaccine trials. Services encompass study start-up through trial execution including critical lab testing needed to start and drive your vaccine studies forward while optimizing the quality of clinical and commercial outcomes....
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – November 4, 2014 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 13,303,666 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”), of which Quintiles intends to repurchase from the underwriter a number of shares having an aggregate value of approximately $250 million. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in this offering.  Quintiles’ per-share...
Read More
Press Release
Research Triangle Park, NC – October 30, 2014 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the third quarter ended September 30, 2014. 13.8% consolidated service revenue growth - Integrated Healthcare Services segment grew service revenues by 32.6% compared to the third quarter of 2013 Consolidated book-to-bill ratio of 1.42 results from 12.8% growth in net new business compared to the third quarter of 2013 Third quarter diluted adjusted EPS increased 22.6% to $0.65 per share compared to the third quarter of 2013 Third quarter GAAP reported diluted EPS increased 42.0% to $0.71 per share compared to the third quarter of 2013 Adjusted full year 2014 service revenue guidance of...
Read More